Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-202 in PSMA-positive clear cell renal cell carcinoma
NCT02607553Phase 2Completed
- Sponsor
- Inspyr Therapeutics
- Start
- Jun 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mipsagargin in clear cell renal cell carcinoma (ccRCC), sponsored by Inspyr Therapeutics. Primary endpoint: Clinical activity at 8 weeks. Started Jun 2016; status: completed.
02
Drugs
mipsagargin
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02607553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607553.